MaxCyte (MaxCyte) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MaxCyte is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of MaxCyte's Risk Assessment

For the Medical Devices subindustry, MaxCyte's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MaxCyte's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MaxCyte's Risk Assessment falls into.

MaxCyte (NAS:MXCT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MaxCyte Risk Assessment Related Terms

Thank you for viewing the detailed overview of MaxCyte's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte (MaxCyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

MXCT:UK MYE0:Germany MYE0:Germany

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Executives

John Joseph Johnston	director	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler	director, officer: President and CEO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross	officer: EVP, Global Sales	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky	officer: Chief Financial Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen	officer: Chief Scientific Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy	officer: Chief Financial Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud	officer: EVP and General Counsel	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz	officer: SVP and CAO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell	director	C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke	director	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Thompson J Stark Phd	director